June 19, 2019

iBio Announces First Agreement for Fill-Finish Services

NEW YORK, June 19, 2019 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”) today announced the activation of its new cGMP sterile fill-finish services operation via the signing of a supply agreement with a clinical-stage ...

Continue Reading

June 3, 2019

iBio Launches New Sterile Fill-Finish Services

NEW YORK, June 03, 2019 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”) today introduced new cGMP sterile fill-finish capabilities for pharmaceutical products, including monoclonal antibodies, viral vectors, and other ...

Continue Reading

April 1, 2019

iBio Announces Appointment of Thomas F. Isett to Board of Directors

Accomplished Life Science Executive with Deep Bioprocess Experience NEW YORK, April 01, 2019 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO), a biologics contract manufacturer and product developer with proprietary, “green” technologies for ...

Continue Reading

October 2, 2018

iBio and CC-Pharming Hold First Design and Strategy Meeting

Texas Meeting Initiates Plan to Bring Economical, Plant-Derived Rituximab to China Market NEW YORK, Oct. 02, 2018 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) today announced the beginning of a four-day design and strategic planning meeting with ...

Continue Reading

July 9, 2018

iBio Establishes Strategic Commercial Relationship with CC-Pharming Ltd. of Beijing, China

NEW YORK, July 09, 2018 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) today announced the commencement of a strategic commercial relationship with CC-Pharming Ltd. of Beijing, China for joint development of products and manufacturing facilities for ...

Continue Reading
1